Alpha Tau Medical (DRTS) Cash from Financing Activities (2021 - 2022)

Alpha Tau Medical (DRTS) posted Cash from Financing Activities of $14.8 million for Q2 2022, down 81.93% sequentially from $82.0 million in Q1 2022.

Analysis

Alpha Tau Medical (DRTS) Cash from Financing Activities (2021 - 2022) Analysis & Trends

Alpha Tau Medical has reported Cash from Financing Activities for 2 years, with the latest figure at $14.8 million in Q2 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Financing Activities (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-426.70 Mn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	-1.22 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	14.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	2.42 Bn
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	-6.05 Mn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	36.24 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-273.15 Mn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	27.18 Mn
10	Alpha Tau Medical	1.21 Bn	1.11 Bn	-	-

Historic Data

Download Data